GlaxoSmithKline PLC (GSK) racked up ￡1.4 billion (US$1.9 billion) in COVID-19-related sales last year, largely for antibody drug sotrovimab, as it beat quarterly forecasts in its first earnings report since rejecting a bid from Unilever PLC for its consumer arm.
The British drugmaker said it expected pandemic-related sales this year to be at similar levels to last year, but said these would contribute less to profit due to lower margins on its antibody treatment.
The performance is a boost for chief executive Emma Walmsley as GSK’s COVID-19 vaccines projects have fallen behind and the impending spinoff of the consumer venture with Pfizer Inc has put the future of the pharmaceuticals business in focus.
Photo: AFP
Adjusted earnings for the group stood at ￡0.256 per share for the three months to Dec. 31 last year, while turnover rose 13 percent to ￡9.53 billion at constant currency rates, topping a consensus of ￡0.238 apiece on sales of ￡9.49 billion.
“We have ended the year strongly, with another quarter of excellent performance ... and we enter 2022 with good momentum,” Walmsley said. “This is going to be a landmark year for GSK.”
The company is pressing on with the spinoff of the consumer arm, home to brands such as Sensodyne toothpaste and Advil painkiller, after rejecting a ￡50 billion buyout offer for the unit from Unilever in December.
GSK’s sotrovimab, developed with Vir Biotechnology Inc, is one of the few COVID-19 treatments shown to have worked against the fast-spreading Omicron variant of SARS-CoV-2, spurring huge demand. It was amongst GSK’s top selling offerings last year.
Countries around the world have ordered 1.7 million doses of sotrovimab, with the US striking a second deal for the treatment last month. Canada and the EU have also secured supplies.
Sales of sotrovimab, branded Xevudy, stood at ￡828 million in the fourth quarter, up from ￡114 million in the third quarter and well above market expectations of ￡774 million.
Revenue from shingles vaccine Shingrix, a key earnings driver over past quarters, slipped 7 percent to ￡597 million, as pandemic restrictions kept the elderly target group from seeking the shot, but sales surpassed consensus of ￡548 million.
The company said that sales this year, after the spinoff of its consumer arm, were expected to grow 5 to 7 percent and adjusted operating profit to grow 12 to 14 percent, including a boost from a settlement with Gilead Sciences Inc, but not sales of its COVID-19 products.
Semiconductor business between Taiwan and the US is a “win-win” model for both sides given the high level of complementarity, the government said yesterday responding to tariff threats from US President Donald Trump. Home to the world’s largest contract chipmaker, Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), Taiwan is a key link in the global technology supply chain for companies such as Apple Inc and Nvidia Corp. Trump said on Monday he plans to impose tariffs on imported chips, pharmaceuticals and steel in an effort to get the producers to make them in the US. “Taiwan and the US semiconductor and other technology industries
SMALL AND EFFICIENT: The Chinese AI app’s initial success has spurred worries in the US that its tech giants’ massive AI spending needs re-evaluation, a market strategist said Chinese artificial intelligence (AI) start-up DeepSeek’s (深度求索) eponymous AI assistant rocketed to the top of Apple Inc’s iPhone download charts, stirring doubts in Silicon Valley about the strength of the US’ technological dominance. The app’s underlying AI model is widely seen as competitive with OpenAI and Meta Platforms Inc’s latest. Its claim that it cost much less to train and develop triggered share moves across Asia’s supply chain. Chinese tech firms linked to DeepSeek, such as Iflytek Co (科大訊飛), surged yesterday, while chipmaking tool makers like Advantest Corp slumped on the potential threat to demand for Nvidia Corp’s AI accelerators. US stock
The US Federal Reserve is expected to announce a pause in rate cuts on Wednesday, as policymakers look to continue tackling inflation under close and vocal scrutiny from US President Donald Trump. The Fed cut its key lending rate by a full percentage point in the final four months of last year and indicated it would move more cautiously going forward amid an uptick in inflation away from its long-term target of 2 percent. “I think they will do nothing, and I think they should do nothing,” Federal Reserve Bank of St Louis former president Jim Bullard said. “I think the
Cryptocurrencies gave a lukewarm reception to US President Donald Trump’s first policy moves on digital assets, notching small gains after he commissioned a report on regulation and a crypto reserve. Bitcoin has been broadly steady since Trump took office on Monday and was trading at about US$105,000 yesterday as some of the euphoria around a hoped-for revolution in cryptocurrency regulation ebbed. Smaller cryptocurrency ether has likewise had a fairly steady week, although was up 5 percent in the Asia day to US$3,420. Bitcoin had been one of the most spectacular “Trump trades” in financial markets, gaining 50 percent to break above US$100,000 and
RSS